🟢 Opus Genetics is trading 5% up in after-hours trading after positive gene therapy findings

Opus Genetics is trading at $4.26, up +5.19%, amid positive clinical findings from its OPGx-BEST1 and OPGx-LCA5 gene therapy programs.

• At Retina in Rio 2026, data showed improved retinal sensitivity in three of four evaluable OPGx-BEST1 participants and vision improvements among OPGx-LCA5 participants.
• The company expects OPGx-LCA5 Phase 3 dosing to begin in the fourth quarter of 2026.